Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses.

Globale Forschungsergebnisse zu Lutetium-177-PSMA bei Prostatakrebs: bibliometrische und altmetrische Analysen.

Journal

Nuklearmedizin. Nuclear medicine
ISSN: 2567-6407
Titre abrégé: Nuklearmedizin
Pays: Germany
ID NLM: 7609387

Informations de publication

Date de publication:
23 Jan 2024
Historique:
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

The integration of innovative radio-pharmaceutical agents targeting prostate-specific membrane antigen (PSMA) within nuclear medicine has transformed prostate cancer detection and management. This study aims to investigate the present landscape of [ We systematically probed the Scopus repository for relevant [ Spanning January 2015 to July 2023, the study encompassed 466 articles concerning [ The findings highlight the growing interest and advancements in the utilization of [

Identifiants

pubmed: 38262473
doi: 10.1055/a-2221-3036
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Rakan Al-Rashdan (R)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan.

Haneen Al-Abdallat (H)

School of Medicine, The University of Jordan, Al-Jubeiha, Jordan.

Mike Machaba Sathekge (MM)

Nuclear Medicine, University of Pretoria, Pretoria, South Africa.

Siroos Mirzaei (S)

Institute of Nuclear Medicine with PET-Center, Wilhelminen Hospital, Vienna, Austria.

Mohammed Shahait (M)

Surgery Department, Clemenceau Medical Center Dubai, Dubai, United Arab Emirates.

Khaled Al-Khawaldeh (K)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan.
Nuclear Medicine, King Hussein Medical Center (KHMC), Amman, Jordan.

Ahmed Saad Abdlkadir (AS)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan.

Szeting Lee (S)

Department of Molecular Imaging and Therapy, Austin Health, Victoria, Australia.

Akram Al-Ibraheem (A)

Nuclear Medicine, King Hussein Cancer Center (KHCC), Al-Jubeiha, Jordan.
School of Medicine, The University of Jordan, Al-Jubeiha, Jordan.

Classifications MeSH